Additionally, cancer treated with C3a, C3aR and/or C5aR inhibitors showed less resistance to therapy or had restricted metastasis [29,32,40], arguing that C3a may have pro-tumorigenic activities, yet poorly characterized mechanisms. This evidence concerns the gene C3AR1 and cancer.